Journal article
Human papillomavirus in adolescents: Lessons learned from decades of evaluation
YL Jayasinghe, EE Moore, SN Tabrizi, SR Grover, SM Garland
Journal of Paediatrics and Child Health | WILEY | Published : 2013
Abstract
Knowledge regarding the natural history of human papillomavirus (HPV) infection and its clinical sequelae in adolescents has increased significantly over the last decade; as a result, there have been world-wide recommendations for less aggressive Pap screening and management of cervical dysplasias in young women. It is important that adolescent health providers understand these issues, as knowledge of HPV and its sequelae in the Australian community is limited, despite the introduction of a national immunisation programme. Parents and young women have expressed a desire for further information to make informed choices. This paper reviews the natural history of HPV infection in adolescents an..
View full abstractGrants
Awarded by NHMRC
Funding Acknowledgements
The authors do not have any commercial or financial interests with any material presented in this manuscript. Dr Jayasinghe has received funding from the Royal Australian College of Obstetricians and Gynaecologists (Arthur Wilson Memorial Scholarship), the Cancer Council of Victoria (Postgraduate Research Scholarship) and the Royal Australian College of Sexual Health Physicians (Novartis Scholarship). Her PhD is being supported by a Victorian Cancer Agency Tumour Stream Grant and an NHMRC program grant 568971. Dr Moore has received funding from Commonwealth Serum Laboratories (Victoria, Australia) to travel to the International Papillomavirus Conference 2010. Professor Garland has received funding from Merck & Co., Inc. (Whitehouse Station, NJ) through her institution to conduct clinical trials of the HPV vaccine. Professor Garland has received advisory board fees and grant support from Commonwealth Serum Laboratories (Victoria, Australia) and GlaxoSmithKline (Research Triangle Park, NC), and lecture and consultancy fees from Merck & Co., Inc. She has previously owned stock in Commonwealth Serum Laboratories and has received grant support through her institution from GlaxoSmithKline to conduct clinical trials for human papillomavirus and cervical cancer vaccines.